Selective agonist for the vascular receptor of 5-hydroxytryptamine-1 (5-HT1, serotonin) with vasoconstrictor action at the intracranial level.  
Indicated in acute migraine attack. Subcutaneous, oral or intranasal administration in a daily dose.

It is excreted in breastmilk in clinically insignificant amounts (Wojnar 1996).

Its very low oral bioavailability impedes its transfer breastmilk to infant plasma, except in premature infants and the immediate neonatal period when there may be greater intestinal permeability.

Several medical assocoations, experts and expert consensus consider its use to be safe during breastfeeding (Hale 2019, Briggs 2017, Bordini 2016, Becker 2015, Amundsen 2015, Davanzo 2014, Worthington 2013, Hutchinson 2013, Duong 2010, Cassina 2010, Jürgens 2009, Marcus 2008, Raña 2008, MacGregor 2007, Loder 2007).

American Academy of Pediatrics: this medication is usually compatible with breastfeeding (AAP 2001).